Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 46, Issue 6, 2007, Pages 701-710

  Sonuga Barke, Edmund J S ^a   Coghill, David ^b   Markowitz, John S ^c   Swanson, James M ^d   Vandenberghe, Mieke ^e   Hatch, Simon J ^f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UCB PHARMA   (Belgium)

^f Simon Hatch Consulting Inc   (United States)

Author keywords

Methylphenidate; Response; Sex differences

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; SEX FACTORS;

EID: 34249287980     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/chi.0b013e31804659f1     Document Type: Article

References (45)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Press
2. Andersen SL, Teicher MH (2000), Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 24:137-141
3. Arnsten AFT, Dudley G (2005), Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and DA D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Function 1:2
4. Bawden D (1993), Predicting methylphenidate response with neurometric testing: case studies. In: Handbook of Childhood Impulse Disorders and ADHD: Theory & Practice, Koziol LF, Stout CE, Ruben DH, eds. Springfield, IL: Charles C Thomas, pp 60-77
5. Bhatt SD, Dluzen DE (2005), Dopamine transporter function differences between male and female CD-1 mice. Brain Res 1035:188-195
6. Biederman J, Faraone SV (2005), Attention-deficit hyperactivity disorder. Lancet 366:237-248
7. Bobb AJ, Addington AM, Sidransky E et al. (2005), Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B 134B:67072
8. Cheon KA, Ryu YH, Kim JW, Cho DY (2005), The homozygosity for 10-repeat in allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15:95-101
9. Federici M, Geracitano R, Bernardi G, Mercuri NB (2005), Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol Psychiatry 57:361-365
10. Focalin XR (dexmethylphenidate hydrochloride) Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR_PPI. pdf. Accessed February 1, 2007
11. Gaub M, Carlson CL (1997), Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 36:1036-1045
12. Ghandi M, Aweeka F, Greenblatt RM, Blaschke TF (2004), Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499-523
13. Gomez R, Harvey J, Quick C, Scharer I, Harris G (1999), DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry 40:265-274
14. Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, Hatch SJ (2002), Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175-184
15. Gray JR, Kagan J (2000), The challenge of predicting which children with ADHD will respond positively to methylphenidate. J Appl Dev Psychol 21:471-489
16. Greenhill L, Kollins S, Abikoff H et al. (2006), Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1284-1293
17. Hazell P, Lewin T, Sly K (2005), What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder? Aust N Z J Psychiatry 39:354-358
18. Hu M, Crombag HS, Robinson TE, Becker JB (2004), Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29:81-85
19. Krause KH, Krause J, Dresel SH, LaFougere C, Ackenheil M(2004), Response tomethylphenidate in adult ADHD patients depends on striatal dopamine transporter density. Eur Neuropsychopharmacol 14:S389-S390
20. Lavalaye J, Linszen DH, Booij J (2001), Dopamine transporter density in young patients with schizophrenia assessed with [(123)] FP-CIT SPECT. Schizophr Res 47:59-67
21. Maniadaki K, Sonuga-Barke EJS, Kakouros E (2003), Trainee nursery teachers' perceptions of disruptive behaviour disorders; the effect of sex of child on judgements of typicality and severity. Child Care Health Dev 29:433-440
22. Markowitz JS, DeVane LC, Pestreich LK, Patrick KS, Muniz RA (2006), Comprehensive in vitro screening of d-, l- and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16:687-698
23. Markowitz JS, Straughn AB, Patrick KS (2003), Advances in the pharmacotherapy of attention deficit hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 23:1281-1299
24. Modi NB, Wang B, Noveck RJ, Gupta SK (2000), Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 40:1141-1149
25. Mozley LH, Gur RC, Mozley PD, Gur RE (2001), Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158:1492-1499
26. MTA Cooperative Group (1999), Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder - the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 56:1088-1096
27. Owens EB, Hinshaw SP, Kraemer HC et al. (2003), Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 71:540-552
28. Patrick KS, DeVane CL, Malcolm RJ, Minhinnett RR, Markowitz JS (2005b), Influence of ethanol and gender on methylphenidate bioavailability, metabolism and response. Abstract presented at the American Association of Clinical Pharmacology Annual Meeting, September 11-12, Rockville, MD
29. Patrick KS, González MA, Straughn AB, Markowitz JS (2005a), New methylphenidate formulations for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Drug Deliv 2:121-143
30. Pentikis H (2005), Sex-based differences in the pharmacokinetics of methylphenidate. Poster presented at the 52nd Meeting of the American Academy of Child and Adolescent Psychiatry, October 18-23, Toronto
31. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA (2005), Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 6:225-234
32. Rivest R, Falardeau P, Dipaolo T (1995), Brain dopamine transporter-gender differences and effect of chronic haloperidol. Brain Res 692:269-272
33. Robison LM, Skaer TL, Sclar DA, Galin RS (2002), Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 16:129-137
34. Roth ME, Cosgrove KP, Carroll ME (2004), Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev 28:533-546
35. Schwartz JB (2003), The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:102-121
36. Schweitzer JB, Lee DO, Hanford RB, Tagamets AM, Hoffman JM, Grafton ST, Kilts CD (2003), A positron emission tomography study of methylphenidate in adults with ADHD: alternations in resting blood flow and predicting treatment response. Neuropsychopharmacology 28:967-973
37. Seidman LJ, Biederman J, Monuteaux MC, Valera E, Doyle AE, Faraone SV (2005), Impact of gender and age on executive functioning: do girls and boys with and without attention deficit hyperactivity disorder differ neuropsychologically in preteen and teenage years? Dev Neuropsychol 27:79-105
38. Sonuga-Barke EJS (2005), Causal models of ADHD: from simple single deficits to multiple developmental pathways. Biol Psychiatry 57:1231-1238
39. Sonuga-Barke EJS, Swanson J, Coghill D, DeCory H, Hatch SJ (2004), Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28
40. Swanson JM (1992), School-Based Assessments for ADD Students . Irvine, CA: K.C. Publishing
41. Swanson JM, Wigal SB, Wigal T et al., COMACS Study Group (2004), A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 113:E206-E216
42. Vitiello B, Heiligenstein JH, Riddle MA, Greenhill LL, Fegert JM (2004), The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biological Psychiatry 56:3-9
43. Volkow ND, Wang GJ, Fowler JS et al. (2001), Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:U1-U5
44. Volkow ND, Wang GJ, Fowler JS et al. (2004), Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161:1173-1180
45. White TL, Justice AJH, de Wit H (2002), Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741